Nitric oxide synthase
Family in Homo sapiens that 1 drug acts on.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
- Genes: 3
Who is on it, and how far along
Every drug ChEMBL records acting on NOS1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Tilarginine | Phase 3 | Arginox Pharmaceuticals | Small molecule | InhibitorNitric oxide synthase inhibitor | 3 |
| Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) | Tilarginine | Phase 2 | Recruiting | The Methodist Hospital Research Institute | Dec 21, 2022 |
| Passive Limb Movement: A Tool to Assess Vascular Health and Guide Rehabilitation | Tilarginine | — | Active, not recruiting | VA Office of Research and Development | Aug 10, 2018 |
| : Vascular Function in Health and Disease | Tilarginine | Phase 1 | Recruiting | D. Walter Wray | Nov 17, 2016 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4630725, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets